Gefitinib
- Generic Name
- Gefitinib
- Brand Names
- Iressa, Gefitinib Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C22H24ClFN4O3
- CAS Number
- 184475-35-2
- Unique Ingredient Identifier
- S65743JHBS
- Background
Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa.
- Indication
For the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer
- Associated Therapies
- -
Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2004-07-19
- Last Posted Date
- 2013-06-19
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00005806
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-07-12
- Last Posted Date
- 2017-02-27
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 31
- Registration Number
- NCT00086957
- Locations
- 🇺🇸
Tower Cancer Research Foundation, Beverly Hills, California, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸Hematology Oncology Consultants-Hemet, Hemet, California, United States
Capecitabine, Oxaliplatin, and Gefitinib in Treating Patients With Metastatic Colorectal Cancer
- Conditions
- First Posted Date
- 2004-07-12
- Last Posted Date
- 2013-02-01
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 10
- Registration Number
- NCT00087334
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Gefitinib and Docetaxel in Treating Patients With Advanced Solid Tumors
- Conditions
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2013-01-17
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00084786
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Calcitriol and Gefitinib With or Without Dexamethasone in Treating Patients With Advanced Solid Tumors
- Conditions
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2014-01-13
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 53
- Registration Number
- NCT00084708
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2016-01-20
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 61
- Registration Number
- NCT00085566
- Locations
- 🇪🇸
Vall d'Hebron University Hospital, Barcelona, Spain
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Gefitinib Followed By Surgery in Treating Women With Ductal Carcinoma In Situ of the Breast
- Conditions
- First Posted Date
- 2004-05-19
- Last Posted Date
- 2013-02-25
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 1
- Registration Number
- NCT00082667
- Locations
- 🇺🇸
Meharry Medical College, Nashville, Tennessee, United States
🇺🇸Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Gefitinib, Paclitaxel, and Radiation Therapy in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck
- Conditions
- First Posted Date
- 2004-05-17
- Last Posted Date
- 2012-03-15
- Target Recruit Count
- 30
- Registration Number
- NCT00083057
- Locations
- 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
🇺🇸NCI - Metabolism Branch;MET, Bethesda, Maryland, United States
ZD 1839 Plus Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2004-04-26
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT00006049
- Locations
- 🇺🇸
AstraZeneca Pharmaceuticals LP, Wilmington, Delaware, United States
ZD 1839 Plus Combination Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2004-04-26
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT00006048
- Locations
- 🇺🇸
AstraZeneca Pharmaceuticals LP, Wilmington, Delaware, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.